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To better define a mechanism underlying the increase in expression of certain proinflammatory chemokines during HIV-1
infection, we analyzed the effect of X4 HIV-1 infection on C, C-C, and C-X-C chemokine mRNA levels. We demonstrate that
X4 HIV-1 infection augments the expression of RANTES, IP-10, MCP-1, and Ltn in peripheral blood mononuclear cells
(PBMCs). R5 HIV-1 also induces an increase in both IP-10 and MCP-1 production. Binding of UV-inactivated HIV-1 elevates
MCP-1, RANTES, MIP-1a, MIP-1b, and IL-8 expression, but fails to alter the production of IP-10, suggesting that the induction
of IP-10 is dependent on downstream events following viral internalization. Indeed, recombinant gp120 alone was able to
stimulate an eightfold increase in MCP-1 expression, but was unable to induce any detectable increase in IP-10 protein.
HIV-induced modulation of chemokine expression suggests a mechanism by which HIV-infected monocytes and T cells might
recruit target cells to sites of active viral replication, thus potentially aiding in the spread of the virus. © 2002 Elsevier Science
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Cytokines play a pivotal role in the regulation and
function of immune cells during viral infection (for review,
see Poli et al., 1995). Chronic immune activation during
HIV infection, as well as HIV-specific enhancement of
expression of certain cytokines, results in the dysregu-
lation of the cytokine network (Poli et al., 1995). For
example, HIV infection is associated with an increase in
the production of proinflammatory cytokines, especially
during the later stages of disease (Poli et al., 1995). High
levels of TNF-a, IL-1b, and IFNg are secreted by cultured
peripheral blood mononuclear cells (PBMCs) (Hober et
al., 1989; Roux-Lombard et al., 1989; Voth et al., 1990;
Vyakarnam et al., 1991), while elevated levels of TNF-a
are produced by macrophages (Antinori et al., 1992)
isolated from HIV-infected donors. Elevated levels of
TNF-a, IL-6, and IL-1b have been detected in the serum
(Arditi et al., 1991; Breen et al., 1990), IL-1b and IL-6 in the
cerebrospinal fluid (Gallo et al., 1989), TNF-a and IL-1b in
the intestinal mucosa (Kotler et al., 1993), and IFNg in the
lymph nodes (Boyle et al., 1993; Emilie et al., 1990) of
HIV-infected individuals. The alteration of the cytokine
network observed during HIV infection also includes the
progressive loss of the ability to produce immunoregu-
latory cytokines, such as IL-2 and IL-12, which are critical
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6for effective cell-mediated immune responses (Clerici et
al., 1993; Schulick et al., 1993). Alterations in the balance
of cytokine production may directly contribute to HIV
pathogenesis by further stimulating HIV replication, by
suppressing the ability of the immune system to mount a
strong antiviral response, or by inducing cytokine-medi-
ated cytopathic effects (Fauci, 1996).
While the aforementioned cytokines play a pivotal role
in regulating the progression of HIV infection, the role of
chemokines in the transmission and susceptibility to HIV
infection is less well understood. Although many chemo-
kines have been studied in the context of suppression of
HIV replication, their individual contributions to the re-
cruitment of leukocytes into the brain and peripheral
immune organs during disease progression have not
been fully defined. Monocytes have been proposed to
play an important role in primary HIV infection, serving
as an important target for R5 strains of HIV both during
the initial stages of infection and during entry into the
central nervous system (Koenig et al., 1986; Roos et al.,
1992; Zhu et al., 1993). The emergence of X4 HIV strains
later in the course of the disease generally correlates
with CD41 T cell decline and, finally, the development of
AIDS (Cheng-Mayer et al., 1991; Tersmette et al., 1989).
We wanted to determine whether X4 and R5 HIV-1 infec-
tion of PBMCs could result in altered production of che-
mokines, thus potentially selectively recruiting certain
cellular targets during progression of HIV-1 disease. Our
results reported here show that both R5 and X4 HIV-1-
infected PBMCs exhibit increased production of C, C-C,
and C-X-C chemokines, including monocyte chemotactic
7HIV-1 INDUCTION OF CHEMOKINESprotein (MCP)-1, a potent activator of monocyte function
and a major inducer of monocyte recruitment, and IFNg-
inducible protein (IP)-10, a major chemoattractant of ac-
tivated T cells. Moreover, in activated PBMCs, X4 HIV-1
significantly enhances the expression of lymphotactin
(Ltn). Interestingly, we show here that X4 HIV-1 infection
exerts its effects on MCP-1 and IP-10 through two distinct
and separate mechanisms. The induction of MCP-1 by
X4 HIV-1 is mediated by events which occur as a part of
virus binding to the cell surface, while events which are
further “downstream” of virus infection result in an in-
crease in IP-10 expression.
RESULTS
Infection with a X4 strain of HIV-1 results in a
significant increase in the levels of RANTES, IP-10,
and MCP-1 mRNA
To determine whether HIV-1 infection alters chemo-
kine production in nonactivated PBMCs, cells from five
donors were isolated and infected with the IIIB (X4) strain
of HIV. We have previously shown (Wetzel et al., 2000)
that during 24–96 h in culture, chemokine transcripts can
be detected at 24 h, and peak at 48 and 72 h in culture.
Therefore, total RNA was isolated 48 h after infection,
and the levels of chemokine transcripts were determined
by RNAse protection analysis. Examination of chemokine
levels from each of five donors revealed that infection of
nonactivated PBMCs with an X4 strain of HIV-1 resulted
in an elevation in RANTES, IP-10, and MCP-1 expression
(Figs. 1 and 2), while levels of MIP-1a, MIP-1b, and IL-8
showed only a modest enhancement. Quantitation of the
RNase protection analysis (Fig. 2) shows that X4 HIV-1
infection of non-PHA-activated PBMCs resulted in a
modest 1.5-fold increase in RANTES mRNA levels and a
threefold increase in MCP-1 mRNA levels (Fig. 1, lanes 1
and 2, and Figs. 2D and 2G, respectively). Interestingly,
IP-10 expression was detected by non-PHA-activated
PBMCs after infection with an X4 HIV-1 strain (Fig. 1,
lanes 1 and 2; Fig. 2C). In contrast, a nonsignificant
elevation of MIP-1a, MIP-1b, and IL-8 mRNA levels was
observed after X4 HIV-IIIB infection of non-PHA-activated
PBMCs (Fig. 1, lane 2, and Figs. 2F, 2E, and 2B, respec-
tively). In addition, Ltn mRNA expression by nonactivated
PBMCs was not detected in any of the five donors ex-
amined (Fig. 1, lanes 1 and 2; Fig. 2A), and X4 HIV-1
infection did not induce its expression (Fig. 1, lane 2; Fig.
2A).
These results show that nonactivated cells respond to
HIV infection by selectively increasing the expression of
certain chemokines. We next attempted to determine
whether the nonactivated cells in these studies could be
productively infected with X4 HIV-1. Nonactivated, HLA-
DR-negative PBMCs were obtained by fluorescence-ac-
tivated cell sorting and were subjected to infection with
HIV-IIIB. We observed that nonactivated PBMCs pro-duced modest, but detectable, HIV-1 p24 protein as early
as 24 h postinfection (11 ng/ml at 24 h, 16.4 ng/ml at 48 h,
and 21.3 ng/ml at 72 h postinfection). Moreover, nonac-
tivated cells also clearly expressed the mature HIV-1
coreceptors. Specifically, 43% of the HLA-DR-/CD31 sub-
population expressed CXCR4, while 5% of the HLA-DR-/
CD141 subpopulation expressed CXCR4. Thus, the ele-
vated levels of MCP-1, RANTES, and IP-10 transcripts
shown above (Figs. 1 and 2) appear to be associated
with HIV-1 infection of the nonactivated PBMCs.
Activation state of the target cells may also play a role
in the outcome of chemokine production, since various
cell types and activation states produce distinct chemo-
kine profiles. To test this hypothesis, experiments were
carried out to determine the effect of X4 HIV-1 infection of
activated PBMCs on chemokine expression. Cells were
activated with PHA for 24 h, followed by X4 HIV-1 infec-
tion. Forty-eight hours after infection, chemokine tran-
FIG. 1. The effect of X4 HIV-1 infection on chemokine mRNA levels in
PBMCs. PBMCs were cultured with medium alone or activated with
PHA (5 mg/ml), and 24 h later infected with X4 HIV-1 (strain IIIB).
Forty-eight hours after infection, the level of chemokine mRNA was
determined by RNAse protection assay. Results are presented as
individual protected fragments for Ltn, RANTES, IP-10, MIP-1b, MIP-1a,
MCP-1, IL-8, and the housekeeping gene, L32. Autoradiogram shows
the effect of X4 HIV-1 on chemokine production by nonactivated PBMCs
and shows a representative of the result from one of five different
donors for nonactivated PBMCs or seven different donors for PHA-
activated PBMCs.script levels were measured by RNAse protection anal-
ysis (Fig. 1, lanes 3 and 4; Fig. 2). In each of seven donors
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Ltn, IL-8, MIP-1a, and MIP-1b chemokine mRNA levels,
while RANTES and MCP-1 mRNA expression was not
altered after activation (Fig. 1, lane 3; Fig. 2). In four of
seven donors analyzed, IP-10 transcripts were not de-
tected in PBMCs 24 h after PHA activation (Fig. 1, lane 3).
However, in those donors expressing detectable consti-
tutive IP-10, the X4 HIV-1 infection did not alter the ex-
pression of this chemokine (Fig. 2C). Interestingly, Ltn
mRNA expression was detected after activation in each
of seven donors examined, and X4 HIV infection in-
creased Ltn levels 3.5-fold (Fig. 1, lanes 3 and 4; Fig. 2A).
Moreover, both RANTES and MCP-1 mRNA production
was augmented after X4 HIV-1 infection of activated cells
by twofold (Fig. 1, lane 4; Figs. 2D and 2G). X4 HIV-1-
infection of activated PBMCs did not result in a signifi-
cant change in MIP-1a or MIP-1b (Fig. 1, lanes 3 and 4;
Figs. 2E and 2F), a result which is consistent with the
data from infection of nonactivated cells. In contrast to
the nonactivated PBMCs, X4 HIV-1-infected activated
cells produced a twofold greater level of IL-8 than unin-
FIG. 2. The effect of X4 HIV-1 infection on chemokine mRNA levels in
PBMCs. Cells were cultured with medium alone or activated with PHA
(5 mg/ml), and 24 h later infected with X4 HIV-1 (strain IIIB). Forty-eight
hours after infection, the level of chemokine mRNA was determined by
RNAse protection assay. Quantitation of chemokines is presented as
the mean (6SD) of triplicate mRNA samples normalized from a single
donor to the housekeeping gene, L32. Values are representative of the
results from seven different donors. Solid bars represent uninfected
cells, and hatch bars represent X4 HIV-1-infected cells. *P , 0.05;
**P , 0.005.fected cells (Fig. 1, lanes 3 and 4; Fig. 2B). These data
suggest that X4 HIV-1 infection of activated PBMCs re-sults in a significant increase in the levels of Ltn, IL-8,
RANTES, and MCP-1.
Infection with X4 HIV-1 results in an increase in
RANTES, IP-10, and MCP-1 protein levels in
nonactivated PBMCs
X4 infection of PBMCs resulted in significant changes
in IP-10, RANTES, and MCP-1 mRNA expression in all
donors. Therefore, we examined the effect of X4 HIV-1
infection on the expression of MCP-1, RANTES, and IP-10
protein levels. Non-PHA-activated and PHA-activated
PBMCs were infected with X4 HIV-1, and chemokine
protein levels were determined by ELISA. In non-PHA-
activated cells, HIV infection significantly increased the
expression of MCP-1, RANTES, and IP-10 protein levels
48 h after infection (Fig. 3), consistent with results ob-
tained at the mRNA level. In contrast, our results show
that X4 HIV infection had no effect on MCP-1 protein
expression by activated cells (Fig. 3A). The basal level of
FIG. 3. Effect of X4 HIV-1 on RANTES, IP-10, and MCP-1 protein levels
expressed by non-PHA-activated and PHA-activated PBMCs. Cells
were cultured with medium alone or activated with PHA (5 mg/ml), and
24 h later, designated cultures were infected with X4 HIV-1 (strain IIIB).
Forty-eight hours after infection, supernatants were removed, and the
concentrations of MCP-1 (A), RANTES (B), and IP-10 (C) protein were
determined for noninfected (solid bars) and infected (hatched bars)
groups. Values represent the mean (6SD) of the triplicate cultures and
are representative of results from seven different donors. *P , 0.05;
**P , 0.005. NS, not significant.
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that any further induction by X4 infection may be masked
by the activation process. On the other hand, our results
showed that RANTES and IP-10 protein levels are signif-
icantly elevated by infection in activated cells (Figs. 3B
and 3C). Interestingly, only three of seven donors ex-
pressed detectable levels of IP-10 mRNA after activation
of PBMCs (Fig. 1, lane 3; Fig. 2C), while at the protein
level, all donors expressed IP-10 after PHA stimulation
(Fig. 3C).
IP-10 and MCP-1, but not RANTES, protein levels are
selectively increased following infection with R5 HIV-1
It has been proposed that the cellular tropism of HIV-1
is largely responsible for establishing a primary infection
(Roos et al., 1992; Zhu et al., 1993). Therefore, we also
examined the effect of infection with R5 strains on the
production of chemokines. Cells were infected with the
R5 HIV-1 strains JRFL, AdaM, or SF162, and levels of
RANTES, IP-10, and MCP-1 were determined. Our results
(Fig. 4) show that both IP-10 and MCP-1 expression was
significantly elevated following infection with each of the
three R5 strains. In contrast, accumulated results from
several experiments showed that there were no signifi-
cant changes in RANTES expression after R5 HIV infec-
tion (data not shown). Interestingly, we found that R5
HIV-1 infection of nonactivated PBMCs resulted in a
FIG. 4. Effect of R5 HIV-1 infection on the production of IP-10 and
MCP-1 protein levels expressed by non-PHA-activated PBMCs. Cells
were cultured for 24 h followed by HIV infection with either R5 HIV-1
strain JRFL, AdaM, or SF162. Forty-eight hours after infection, the
concentrations of IP-10 (A, C, and E) and MCP-1 (B, D, and F) protein
were determined for both noninfected (solid bars) and infected
(hatched bars) cultures. Values represent the mean (6SD) of triplicate
cultures and are representative of results from seven different donors.
**P , 0.005.significant increase in IP-10 and MCP-1 expression.
Therefore, we examined the cell surface expression ofthe R5 HIV-1 coreceptor, CCR5, on freshly isolated PB-
MCs from three different donors and found that 3–12% of
the total population express CCR5 (data not shown).
Moreover, elevated IP-10 and MCP-1 protein levels were
observed in nonactivated PBMCs 48 h after infection, at
a time when 2–20% of the cells are positive for CCR5
(based on results from five different donors).
UV irradiation of X4 HIV-1 inhibits the induction of
IP-10 mRNA and protein levels, whereas MCP-1
mRNA and protein expression remains unchanged
Based on our earlier observation (Figs. 1 and 2) that X4
HIV-1 increases IP-10 and MCP-1 production, we carried
out experiments to determine whether viral binding was
sufficient to induce MCP-1 and/or IP-10 expression. UV-
irradiated (nonreplicating) or nonirradiated (replicative
competent) X4 HIV-1 was added to PBMCs, and chemo-
kine expression was assessed. Our results show that
treatment with UV-irradiated virus resulted in a 21-fold
increase in MCP-1 protein expression (Fig. 5A). In con-
trast, the inactivated X4 HIV failed to induce a significant
increase in IP-10 expression (Fig. 5B). Our results also
show that MCP-1 mRNA levels were increased after
treatment with irradiated HIV-1; however, the irradiated
virus failed to induce an increase in IP-10 mRNA (data
not shown). Interestingly, RANTES, MIP-1a, MIP-1b, and
IL-8 mRNA levels expressed by nonactivated PBMCs
were also elevated after treatment with irradiated virus
(data not shown). These results suggest a mechanism by
FIG. 5. UV-irradiated X4 HIV-1 (nonreplicating) enhances MCP-1
protein; however, it has no effect on IP-10 expression. PBMCs were
cultured for 24 h and then infected with X4 HIV-1 (strain IIIB) (hatched
bars) or with UV-irradiated virus (crosshatched bars). Forty-eight hours
after infection, MCP-1 (A) and IP-10 (B) protein levels were determined
by ELISA. Values represent the mean (6SD) of the triplicate cultures
and are representative of results from three different donors. **P ,
0.005. NS, not significant.
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tion by PBMCs. Our data show that productive viral
infection is required for the induction of IP-10 expression,
while early events associated with viral binding appear
to be sufficient for the induction of MCP-1, RANTES,
MIP-1a, MIP-1b, and IL-8.
Neutralization of HIV-1 with anti-gp120 monoclonal
antibody inhibited the virus-induced production of IP-
10 and MCP-1 protein levels
To determine whether the X4 HIV-induction of MCP-1
is mediated through binding of HIV-gp120 to target cells,
X4 HIV-1 virions were incubated with anti-gp120 and then
added to PBMCs. The results show that treatment with
anti-gp120 monoclonal antibody significantly reduced
the ability of X4 HIV-1 to enhance either MCP-1 or IP-10
expression (Fig. 6). Treatment with isotype-matched con-
trol immunoglobulin consistently had no significant effect
on the ability of HIV to induce the production of these
FIG. 6. Treatment with monoclonal anti-gp120 antibody inhibits the
X4 HIV-1 induction of MCP-1 and IP-10 expression by non-PHA-acti-
vated PBMCs. Prior to infection, X4 HIV-1 (strain IIIB) was treated with
either anti-gp120 (hatched bars) or the IGg2A isotype negative control
(crosshatched bars) for 1 h at 37°C. The virus/antibody mixture was
then added to the non-PHA-activated PBMCs for 2 h. The cells were
washed, and fresh medium was replaced. Seventy-two hours after
treatment, supernatants were collected, and MCP-1 (A) and IP-10 (B)
protein expression was determined. Values represent the mean (6SD)
of the triplicate cultures and are representative of results from three
different donors. *P , 0.05. NS, not significant.chemokines. We interpret these results to indicate that
anti-gp120 monoclonal antibody blocked MCP-1 expres-sion by inhibiting viral binding (Fig. 6A). In addition,
treatment with anti-gp120 monoclonal antibody inhibited
IP-10 expression by blocking binding, thus inhibiting
downstream replicative events (Fig. 6B). These data pro-
vide evidence that gp120-mediated viral binding is re-
quired for the induction of either MCP-1 or IP-10.
Recombinant HIVgp120 increases the production of
MCP-1, while IP-10 levels remain unchanged
Based on the ability of UV-inactivated HIV to induce
MCP-1 expression, we postulated that X4 HIV-1 binding
alone to the cell surface is sufficient to induce MCP-1
expression. To further test this hypothesis, PBMCs were
treated with recombinant gp120, and IP-10 and MCP-1
levels were determined. Our results (Fig. 7) show that
treatment with gp120, at concentrations as low as 1
ng/ml, induced a significant increase in MCP-1 expres-
sion (Fig. 7A). As expected, gp120 administration at con-
centrations as high as 100 ng/ml failed to induce a
detectable increase in IP-10 expression (Fig. 7B). It is
apparent that X4 HIV-1-mediated stimulation of IP-10
expression requires viral internalization and other down-
stream events.
DISCUSSION
In this report, we present evidence that shows that
during the first 48 h after infection with both X4 and R5
strains of HIV-1, there is a significant selective increase
FIG. 7. Recombinant gp120 stimulates MCP-1 protein expression, but
is unable to induce any detectable increase in IP-10 expression. After
an initial 24 h in culture, non-PHA-activated PBMCs were treated with
designated concentrations of HIV-gp120, and after 48 h, MCP-1 (A) and
IP-10 (B) protein expression was determined. Chemokine expression by
PHA-activated PBMCs is included as a positive control (crosshatched
bars). Values represent the mean (6SD) of the triplicate cultures and
are representative of results from three different donors. *P , 0.05;
**P , 0.005. NS, not significant.
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and MCP-1, while RANTES expression is significantly
augmented only by X4 strains. Moreover, our results (Fig.
1) show that X4 HIV-1 infection of nonactivated PBMCs
induces a modest increase in MIP-1a, MIP-1b, and IL-8
mRNA transcripts. The present results are important in
view of earlier studies showing that HIV-1 infection alters
production of several cytokines, resulting in stimulation
of viral replication, suppression of antiviral responses,
and induction of cytokine-mediated cytopathic effects
(Poli et al., 1995). However, the clinical relevance of
elevated levels of chemokines during HIV transmission
and pathogenesis remains to be defined. In this regard,
certain chemokines compete with HIV for shared core-
ceptors, but they also potentially play a crucial role in
attracting noninfected target cells to the site of active
viral infection. A recent report by Weiss et al. (1999)
demonstrated an important role for astrocyte-derived
MCP-1 in mediating migration of monocytes and acti-
vated lymphocytes across an in vitro model of the blood
brain barrier and may support evidence that monocytic
infiltration of the central nervous system is an important
feature of AIDS-related neuropathology and a significant
correlate of dementia (Glass et al., 1995; Price et al.,
1988). In contrast with the aforementioned studies, our
results suggest a mechanism by which HIV-1 infection
modulates chemokine expression in the periphery,
where monocytes and T cells are major cellular targets
for HIV-1.
Interestingly, while Ltn expression was undetectable
in nonactivated cells, X4 HIV-1 infection of activated cells
resulted in an average threefold increase in the mRNA
level. Our results are consistent with previous reports
that Ltn mRNA expression in resting peripheral blood
leukocytes is dependent on activation (Kennedy et al.,
1995; Hedrick and Zlotnik, 1998). In addition, recent stud-
ies suggest that some leukocytes, which play a role in
the initial phases of the inflammatory response (mast
cells, intraepithelial gd T cells, and NK cells), are capable
of producing Ltn, and second, that the kinetics of Ltn
expression upon activation are extremely rapid (Hedrick
and Zlotnik, 1998). Finally, the types of cells that respond
to Ltn are primarily NK cells, and both CD41 and CD81 T
cells (Hedrick and Zlotnik, 1998; Giancarlo et al., 1996). It
can be postulated that Ltn may play a major role in the
antiviral inflammatory response to HIV-1 infection.
A recent report by Greco et al. (1999) demonstrated
that infection of CD41 T cells with R5 HIV-1 resulted in
elevated levels of MIP-1a and MIP-1b following a 2-week
culture period; however, these investigators found that
infection with X4 HIV-1 had either no effect or resulted in
a decrease in the production of either MIP-1a or MIP-1b.
Interestingly, infection with either of the viral phenotypes
led to an increase in RANTES production. Similarly,
Schmidtmayerova et al. (1996) observed the induction of
MIP-1a and MIP-1b expression in human monocytesfollowing infection with R5 virus. Based on the reported
correlation between HIV-1 replication and MCP-1 levels
in the cerebrospinal fluids of AIDS patients with HIV
encephalitis, Mengozzi et al. (1999) found that MCP-1
secretion and expression were consistently upregulated
over constitutive levels in monocyte-derived macro-
phages infected with R5 HIV-1. These data, taken to-
gether with our findings, support the notion that HIV-1
directly regulates the expression of selected chemo-
kines. The data presented in this article suggest a mech-
anism by which HIV-1-infected cells might recruit unin-
fected potential target cells to the site of active viral
replication, thus aiding in the spread of the virus.
The increase in chemokine expression has the poten-
tial to significantly alter the immune response to the
virus. Several recent reports have shown that certain
chemokines can enhance HIV infection (Kelly et al., 1998;
Kinter et al., 1998; Morinchi et al., 1998). Experiments
carried out with RANTES, MIP-1a, MIP-1b, and MCP-1
show enhanced X4 HIV infection when added 48 h prior
to infection, but lose this activity when added at the time
of infection (Dolei et al., 1998). Several explanations for
these results have been suggested. For example, some
of these effects were associated with increased levels of
CXCR4 transcripts and with increased T cell proliferation
(Dolei et al., 1998). More recently, results show that
pretreatment of monocytes and monocyte-derived mac-
rophages with MCP-2 substantially increases R5 HIV
replication (Kelly et al., 1998). On the other hand, a pro-
posed mechanism for RANTES-induced HIV-1 replication
has emerged from recent studies (Trkola et al., 1999),
which have shown that RANTES oligomers bind to gly-
cosaminoglycans on both the virion and the cell mem-
branes, activating a tyrosine-kinase-dependent signal
that enhances viral infectivity. In addition, it is known that
certain chemokines can activate T cells and induce IL-2
production (Price et al., 1988), along with other cell-
activating cytokines such as IL-1, IL-2, and TNF-a, which
elevate HIV replication (Poli et al., 1994).
Results reported here show that infection with X4
HIV-1 results in an increase in RANTES, MIP-1a, MIP-1b,
IL-8, and most profoundly, MCP-1 and IP-10. We exam-
ined the mechanism by which HIV infection mediates
induction of MCP-1 and IP-10 expression and compared
the ability of irradiated and nonirradiated X4 HIV-1 to
induce chemokine expression. The UV irradiation does
not interfere with the process of target cell binding and
fusion, but renders the virus unable to replicate (Hender-
son et al., 1992). Our results show that irradiated X4 virus
retains the ability to induce MCP-1 expression, but was
unable to induce a detectable increase in the expression
of IP-10. These results suggest that productive viral in-
fection is required for the induction of IP-10 expression,
while early events associated with viral binding are most
likely responsible for the induction of MCP-1. A slight
increase in the ability of UV-irradiated HIV-1 to induce
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effects. In addition, we also show that the HIV-1 gp120
induces a significant increase in MCP-1 but not IP-10
expression. These results provide further evidence that
viral gp120 binding to cell surface receptors plays a
major role in mediating the elevation in the level of
MCP-1. Recent studies suggest that the viral envelope
first interacts with the cell surface through the binding of
the gp120 subunit with CD4, followed by a conforma-
tional change in the envelope, and then an additional
binding interaction with the coreceptor (Loetscher et al.,
2000). The formation of this trimeric complex may expose
a region of the envelope protein, which promotes the
fusion of the viral envelope, to the cell membrane. These
events may be sufficient to induce signal transduction
and transcriptional activation without viral replication.
Indeed, recent studies have shown that IFNg, IL-10, and
IL-12 cytokines are elevated following HIV-1 infection or
treatment with HIV-1 gp120 in PBMCs and macrophages
(Gessani et al., 1997). Finally, we show here that neutral-
izing the virus with anti-gp120 blocks viral binding (inhib-
iting the induction of MCP-1), and further downstream,
viral replicative events (inhibiting the induction of IP-10).
The role of viral transcriptional transactivating regulators,
such as tat, nef, vpr, and rev, that might be involved in the
induction of IP-10, is currently under investigation. More-
over, studies to address the mechanism by which R5
HIV-1 modulates IP-10 and MCP-1 are ongoing in our
laboratories.
In summary, our data show that both R5 and X4 HIV-1
strains induced the production of mRNA transcripts for,
and protein expression of, MCP-1 and IP-10 during the
early stages of infection. The physiological consequence
of enhanced levels of MCP-1, a potent activator of mono-
cyte function and a major inducer of monocyte recruit-
ment, could potentially attract noninfected target cells to
the site of active viral replication. Interestingly, the role of
IP-10 during HIV-infection and pathogenesis remains un-
defined; however, elevated levels of IP-10, a major che-
moattractant for activated T cells, may result in the re-
cruitment of a larger number of potential CD41 T cells as
HIV-1 targets. The influx of CD41 T cells would aid in the
switch from the early, asymptomatic R5 phase to later
X4 stages of the disease, correlating with a CD41 T
cell decline and progression to AIDS. The capacity of
HIV infection to selectively enhance proinflammatory
chemokine expression during the initial stages of infec-
tion suggests a mechanism by which HIV-1 may control
host cellular immune factors, potentially aiding in
the progression of disease. Importantly, our data pro-
vide additional evidence for two distinct mechanisms
by which HIV-1 exerts its effects on MCP-1 and IP-10
expression in PBMCs during the initial stages of infec-
tion.MATERIALS AND METHODS
Isolation of PBMCs and culture
PBMCs were obtained from the whole blood of normal
donors and isolated by Ficoll–Paque Plus (Pharmacia
Biotech, Piscataway, NJ) density gradient centrifugation.
Isolated PBMCs were plated at a cell density of 2 3 106
cells/ml in 24-well tissue culture plates. Cell cultures
were maintained in RPMI 1640 medium (Life Technolo-
gies, Rockville, MD) supplemented with 10% heat-inacti-
vated, low-endotoxin fetal calf serum (Hyclone, Logan,
Utah), 10 mg/ml gentamicin reagent solution (Life Tech-
nologies), and 1 mM L-glutamine (Life Technologies).
Designated cultures of PBMCs were treated with HIV-1
gp120 from the HIV-1 MN X4 tropic strain (NCI, Frederick,
MD), using the culture conditions described above. PB-
MCs were cultured in the presence or absence of T cell
mitogen, phytohemagglutinin (PHA), at 5 mg/ml for 18 h.
Supernatants were removed 48 h after HIV-1 gp120 ad-
ministration, and protein ELISA was performed to deter-
mine protein levels of MCP-1 and IP-10.
Viruses
The X4 IIIB and R5 JRFL, AdaM, SF162 strains of HIV
were obtained from the National Institute of Allergy and
Infectious Diseases AIDS Research and Reference Re-
agent Program (Rockville, MD). The IIIB strain of HIV-1
was propagated in the human T cell line, Molt4-IIIB. The
multiplicity of infection (m.o.i.) of the IIIB strain was de-
termined by quantitation of syncytium formed by HIV-
infected lymphocytes when cocultured with exponen-
tially growing CD4-bearing SupT1 cells. All R5 strains of
HIV were propagated in cultures of PBMCs from adult
donors. Virus was concentrated from culture superna-
tants and purified by pelleting at 110,000g for 90 min. The
pellets were gently washed and resuspended in me-
dium. This procedure produces stock virus of between
106 and 107 syncytia-forming units per 0.1 ml. The 50%
tissue culture infectious dose (TCID50) for the R5 virus
was determined using PBMCs. Briefly, graded doses of
virus were inoculated onto PBMCs, and the extent of
replication was measured every 3 days in the culture
fluid by a p24 antigen ELISA. The final titer was calcu-
lated at the peak time of virus production.
HIV-1 infection of PBMCs
Designated cultures of PBMCs were treated with PHA
(5 mg/ml) at a density of 2 3 106 cells/ml. After 24 h in
culture, titered viral strains were resuspended in serum-
free, low-endotoxin RPMI medium and then added to the
PBMCs at an m.o.i. of 0.1. PHA-stimulated and nonstimu-
lated PBMCs cultures were infected for 2 h at 37°C and
washed, and 48 h after infection, cells and supernatant
was harvested to determine chemokine mRNA or protein
levels, respectively.
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Determination of HIV-1 p24 levels was carried out
using an antigen capture assay. A kit for this assay was
obtained from the AIDS Vaccine Program, Biological
Products Laboratory at the Frederick Cancer Research
and Development Center in Frederick, MD and is com-
posed of 96-well plates coated with monoclonal anti-
HIV-1 p24, a primary antibody (rabbit anti-HIV-1 p24 se-
rum), and a secondary antibody (goat anti-rabbit IgG)
(H 1 L) peroxidase-labeled antibody. Dilutions of the
standards and samples were added to the plates and
incubated at 37°C for 2 h. The plates were washed, and
the primary antibody was added and incubated at 37°C
for 1 h. The plates were washed, and the secondary
antibody was added and incubated at 37°C for 1 h. The
plates were washed, peroxidase substrate was added,
and the reaction was stopped by adding 4NH2SO4. The
level of colored product was measured spectrophoto-
metrically at a wavelength of 450 nm.
Cell sorting and FACS analysis of PBMCs
Freshly isolated PBMCs were washed using a buffer
composed of Hanks’ balanced salt solution supple-
mented with 2% endotoxin-free fetal bovine serum (HF
buffer) and suspended at a density of 3.5 3 107 cells/ml.
Cells were incubated with 2% goat serum at 4°C for 30
min. The cells were washed and suspended in 50 ml HF
containing Cy-chrome-conjugated mouse anti-human
HLA-DR (G46-6) (BD Pharmingen, San Diego, CA) for 1 h
at 4°C. The HLA-DR-negative and -positive cells were
separated by FACS, and the DR-negative population was
either set aside for analysis of HIV-1 infectivity or the
cells were subjected to further staining using either flu-
orescein isothiocyanate (FITC)-conjugated mouse anti-
human CD3 (UCHT1) or CD14 (M5E2) together with R-
phycoerythrin (R-PE)-conjugated mouse anti-human
CCR5 (2D7/CCR5) or CSCR4 (12G5). All flow cytometry
was carried out using a Coulter EPICS XL flow cytometric
analyzer (Coulter Corp., Hialeah, FL).
Measurement of chemokine mRNA by RNase
protection analysis
The expression of chemokines was measured by
RNase protection analysis using the RiboQuant Multi-
Probe RNase Protection Assay System (Pharmingen).
Briefly, 10 mg RNA from each sample, isolated using the
RNAzol method (Tel-Test, Friendswood, TX), was allowed
to hybridize in solution with the radiolabeled antisense
RNA probe. The probe is generated to include an RNA
probe set for the human chemokines Ltn, RANTES, MIP-
1a, MIP-1b, IFNg, IP-10, MCP-1, IL-8, and I-309 according
to the manufacturer’s instructions. The hybridized 32P-
labeled probe-transcript duplex was subjected to diges-
tion with RNase, and the protected probes were purifiedand resolved on 5% denaturing polyacrylamide. The gels
were then dried and exposed to a phosphorimaging
screen, and protected fragments were visualized and
quantitated using a Model GS-525 phosphorimager (Bio-
Rad, Hercules, CA). In some cases, both short and long
exposure times are analyzed to obtain accurate data
from relatively abundant and nonabundant transcripts,
respectively. Results are expressed as relative units,
which are calculated after normalizing based on optical
density of the L32 band for each lane.
Measurement of chemokine protein levels by ELISA
The concentration of chemokines present in culture
supernatants was determined by ELISA, using matched
mouse monoclonal or polyclonal antibody capture and
detection antibodies in a sandwich ELISA. Anti-chemo-
kine “capture” antibodies (Pharmingen) used in these
experiments were rabbit polyclonal anti-human RANTES,
monoclonal anti-human MCP-1 (clone 10F7), and mono-
clonal anti-human IP-10 (clone 4D5). The capture anti-
bodies were coated onto plastic microwell plates (Nunc
Maxisorb) and blocked with 1% BSA-containing PBS, and
graded dilutions of culture supernatant or recombinant
standard (Peprotech, Rock Hill, NJ) were added. After
washing, the captured chemokine proteins were de-
tected using biotin-conjugated anti-chemokine “detec-
tion” antibodies (Pharmingen), polyclonal anti-human
RANTES, monoclonal anti-human MCP-1 (clone 5D3-F7),
and monoclonal anti-human IP-10 (clone 6D4), followed
by HRP-linked streptavidin. Following the addition of
ABTS 2,29-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid)
in buffer, the level of colored product was measured
spectrophotometrically (405 nm).
UV irradiation of HIV strains
For the UV source, total emission from a 15-W GE15T8
low-pressure mercury germicidal lamp controlled by a
rheostat was used. Incident (254 nm) UV dose rate was
5 J/m2 for viral inactivation as determined by Latarjet
dosimeter. The kinetics of UV inactivation of HIV-1 infec-
tivity has been previously described (Henderson, 1992).
One-milliliter aliquots of virus RPMI medium was placed
in 60-mm petri dishes and exposed with gentle agitation
to ensure uniform irradiation. Virus samples were kept
on ice before and after irradiation. Virus inactivation was
confirmed by syncytium assays. We observed no syncy-
tium formation of irradiated virus.
Anti-gp120 assays and neutralization with anti-gp120
monoclonal antibody
Monoclonal anti-HIV gp120 MN was a generous gift of
Dr. Oleg Chertov (NCI, Frederick, MD). The nonspecific
antibody control was of the isotype IgG2a (Organon
Teknika Corp., Durham, NC). Final antibody concentra-
tions used in the experiments were 5 mg/ml, a 1:200
14 WETZEL ET AL.dilution of the stocks. In the HIV-induced chemokine
blocking assays, both the anti-gp120 and the IGg2A iso-
type negative control were incubated with HIV-IIIB (X4)
for 1 h at 37°C. The virus/antibody mixture was then
added to PBMCs for 2 h. The cells were washed, and
fresh media was replaced. Seventy-two hours after in-
fection, supernatants were removed and MCP-1 and
IP-10 protein ELISA was performed. The ability of HIV
anti-gp120 MN to neutralize HIV-IIIB was confirmed by
syncytium count as well as HIV P24 ELISA.
Statistics
The data are presented as the mean 6 SD. Where
appropriate, the statistical difference between experi-
mental groups was assessed using the Student’s t test.
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